Exploring a new way to help children with short bowel syndrome absorb nutrients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of RELiZORB, a device designed to predigest fats for children suffering from short bowel syndrome (SBS) who are dependent on intravenous nutrition. The study aims to improve nutrient absorption by attaching the RELiZORB cartridge to the feeding tube, potentially reducing the need for parenteral nutrition and its associated complications. Participants will include children aged 2 to 18 years who have been on parenteral nutrition for an extended period due to their condition. The trial will assess the effectiveness of this approach in enhancing enteral nutrition and overall health outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female patients, ages 2 years to 18 years, inclusive.
2. Diagnosed with SBS, as determined by medical history and PN dependence (i.e. need for PN for \>60 days after intestinal resection or a bowel length \<25% of expected).
3. Congenital or acquired gastrointestinal disease requiring surgical intervention that has occurred at least 3 months prior to screening.
4. Patient is on parenteral lipid and at least 30% of daily caloric and fluid intake has been provided by PN for a least 6 months prior to screening
5. Stable PN nutrition requirement, determined by less than 5% reduction in PN nutrition calories for at least 1 month prior to screening, or at the discretion of the investigator.
6. The patient has a Central Venous Catheter (CVC) at the time of study inclusion.
7. Screening direct bilirubin that is in the normal range for age and is not determined to be clinically significant by the investigator.
8. The patient has an existing feeding tube, receiving enteral nutrition via an enteral feeding pump at a rate\>10ml/hr but \<400 ml/hr, and is able to tolerate at least 10 ml/kg/day enteral nutrition with which the RELiZORB cartridge can be used. The patient can be on bolus or continuous feeds and can use up to 6 cartridges per day for feeding.
9. Stable enteral nutrition requirement with no change in formula composition or rate for at least 1 month prior to screening.
10. The parent or legal guardian of the patient is able to read, understand, and is willing to provide informed consent (and assent, if applicable).
11. The patient (if assent is applicable) or parent or legal guardian of the patient is able to understand the requirements of the study and is willing to bring the patient to all clinic visits and complete all study related procedures (as determined by the investigator).
12. A parent or legal guardian is willing to provide written authorization for the use and disclosure of protected health information.

Exclusion criteria:

1. Other causes of chronic liver disease other than SBS (i.e., hepatitis C, cystic fibrosis, biliary atresia, alpha 1 anti-trypsin deficiency, and Alagille syndrome).
2. The patient has had a bowel lengthening procedure, including but not limited to, a STEP procedure.
3. Any serum triglyceride concentration \>400 mg/dL at screening.
4. Pancreatic insufficiency as defined as the use of pancreatic enzymes within 30 days prior to screening.
5. Evidence of untreated intestinal obstruction or active stenosis, as determined by the investigator.
6. Unstable absorption due to cystic fibrosis or known DNA abnormalities (i.e., familial adenomatous polyposis, Fanconi syndrome) as determined by the investigator.
7. History of microvillus inclusion disease, as determined by medical history.
8. Severe known dysmotility syndrome (i.e., pseudo-obstruction, gastroschisis-related motility disorders), as determined by the investigator.
9. Initiation of teduglutide or other GLP-2 analogues within 6 months of screening
10. Use of growth hormone, or supplemental glutamine within 3 months prior to screening.
11. Use of cisapride within 30 days prior to screening.
12. Active clinically significant pancreatic or biliary disease, as determined by the investigator.
13. Patients are receiving formulas that are not compatible with the RELiZORB cartridge (example, insoluble fiber-containing formulas)
14. Determined by the investigator to be unsuitable for participation for any reason.

Where it's running

• Children's Hospital Los Angeles
  Los Angeles, California, United States Recruiting
• Boston Children's Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Mark Puder, MD, PhD. — Boston Children's Hospital
• Study coordinator: Mark Puder, MD, PhD
• Email: mark.puder@childrens.harvard.edu
• Phone: 617-355-1838

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Resting energy tests in people with normal digestion vs. intestinal failure

  This study tests resting energy expenditure in adults with and without intestinal failure to help tailor nutrition needs.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07714499

• FT1 for adults with short bowel syndrome: a safe, quick-study test

  This trial tests FT1 vs placebo in adults with short bowel syndrome to see if FT1 is safe and helps with their condition.

  Recruiting Phase 2 Chongqing Peg-Bio Biopharm Co., Ltd. · Nanjing, Jiangsu · NCT07704047

• Glepaglutide for adults with short bowel syndrome and intestinal failure

  This trial tests whether glepaglutide 10 mg given twice weekly can reduce the need for parenteral support in adults with short bowel syndrome and intestinal failure.

  Recruiting at 32 sites Phase 3 Zealand Pharma · Chicago, Illinois and 32 other locations · NCT07197944

• Crofelemer for adults with short bowel syndrome and intestinal failure without a colon

  This trial will test whether taking crofelemer three times a day helps adults with short bowel syndrome and intestinal failure who lack a colon and need parenteral support.

  Recruiting at 8 sites Phase 2 Napo Therapeutics, S.p.A. · Aachen and 7 other locations · NCT06904872

• Elemental 028 Extra case series

  This project will try an upgraded Elemental 028 Extra amino-acid feed in adults and children with severe gut problems who need an elemental diet to see if they tolerate it and can stick with it.

  Recruiting Nutricia UK Ltd · Trowbridge · NCT06877923

• Creating a quick quality-of-life questionnaire for people with short bowel syndrome

  This project will try a shorter, easier quality-of-life questionnaire for adults with short bowel syndrome and compare it with the existing SBS QoL tool.

  Recruiting Hospices Civils de Lyon · Pierre-Bénite · NCT06771505

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.